{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-15",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Monroe",
      "state": "NC",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Devices",
      "event_id": "74002",
      "recalling_firm": "Greiner Bio-One North America, Inc.",
      "address_1": "4238 Capital Dr",
      "address_2": "N/A",
      "postal_code": "28110-7681",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide Distribution to CA, FL, IL, KY, NY, PA, VA and Puerto Rico",
      "recall_number": "Z-1923-2016",
      "product_description": "4 ml FX Sodium Fluoride/Potassium Oxalate tube, Ref 454297  VACUETTE Glycolytic Inhibitor Tubes contain an antiglycolytic agent, sodium fluoride, and an anticoagulant, potassium oxalate. The product is suitable for the analysis of blood glucose and lactate",
      "product_quantity": "250,800 pieces (209 cases)",
      "reason_for_recall": "The 4 ml FX Sodium Fluoride/Potassium Oxalate tube may have no or low additive (sodium fluoride and potassium oxalate), which can effect analytical results for glucose and lactate.",
      "recall_initiation_date": "20160426",
      "center_classification_date": "20160607",
      "termination_date": "20160822",
      "report_date": "20160615",
      "code_info": "Lot A151137L"
    }
  ]
}